Hallstar Beauty and Personal Care Innovations Company

Junmeng Biosciences Co., Ltd.

Shanghai Junshi Biosciences Co., Ltd.

Suzhou Junmeng Biosciences Co., Ltd.

Shanghai Junshi Biosciences Inc.

Sap Se

Junshi Biosciences Co., Ltd.

Wuhan Therasource Biosciences Inc.

Shanghai Junshi Bioscience Co., Ltd.

Hui Feng

Shengkui Hu

Hai Wu

Jian Yao

Sheng Yao

Dennis Zlotnik

Kai Chen

Dan Meng

Yuehua Zhou

Meng Wei

Zhiliang Jin

Ruipeng Wang

Jing Jing Zhang

Chul Won Lee

Jing Zhang

Ye Fan

Libo Zhang

Bo Chen

Sunyoung Han

Young Hun Kim

Jongheon Park

Hongchuan Liu

Guanghui Qiu

Hongbing Shu

The present invention provides an antibody or a functional fragment thereof that specifically binds to IL-17A with high affinity. Also provided are a nucleic acid molecule encoding the antibody or the functional fragment thereof disclosed herein, an expression vector and a host cell for expressing the antibody or the functional fragment thereof disclosed herein, and a method for preparing the antibody or the functional fragment thereof disclosed herein. The present invention also provides a pharmaceutical composition comprising the antibody or the functional fragment thereof disclosed herein, and use of the antibody or the functional fragment thereof disclosed herein for treating an immune dysfunction disease.

Anti-IL-17A antibody and use thereof

The present disclosure relates, according to some embodiments, to photostable photoactive compositions comprising (a) at least one photoactive compound that develops within itself an excited state energy when subjected to UV radiation and (b) a block copolymer comprising a plurality of blocks, wherein the block copolymer is operable to quench the excited state energy.

Photostable compositions comprising para-alkoxyl phenyl substituted propenoic acid (APP) copolymer derivatives

The present invention relates to an anti-BTLA antibody or an antigen-binding fragment thereof comprising: at least one light chain CDR domain selected from SEQ ID NOs: 7, 8, 9, 10, 11, 12, 16, 17, 18, 22, 23, 24, 31, 32 and 33, and/or at least one heavy chain CDR domain selected from SEQ ID NOs: 1, 2, 3, 4, 5, 6, 13, 14, 15, 19, 20, 21, 25, 26, 27, 28, 29 and 30. The present invention also relates to a nucleic acid molecule encoding the antibody or the antigen-binding fragment thereof, a corresponding expression vector and a host cell, as well as therapeutic use of the antibody or the antigen-binding fragment thereof, the nucleic acid molecule, the expression vector and the host cell.

Anti-BTLA antibody

Some embodiments include a system, method, and non-transitory medium, with the system including an interface to at least one database product; a stateless ping operator to manage lifecycle events associated with the at least one database product; and a first product-specific ping agent to determine an availability of and generate metrics associated with a plurality of instances of a first specific database product of the at least one database product monitored by the first product-specific ping agent, the first product-specific ping agent receiving an assignment of the plurality of instances of the first specific database product to monitor from the ping operator.

Extensibility to monitor multiple products

The present disclosure relates, according to some embodiments, to a method of determining a quantitatively measured photoprotection of a photoprotective composition, the method comprising: (a) distributing the photoprotective composition in a position in between a drawdown bar and at least one substrate to produce a distributed photoprotective composition; (b) drawing down the distributed photoprotective composition to a thickness on at least one substrate to produce a drawn down sample film; (c) drying the drawn down sample film to produce a dried sample film; (d) measuring a UV absorption of the dried sample film to produce a UV absorption spectrum; (e) determining the quantitatively measured photoprotection of the photoprotective composition from the UV absorption spectrum.

Methods and systems for quantitatively measuring photoprotection

An antibody or a functional fragment thereof that specifically bind to PD-L1 with high affinity, a nucleic acid molecule that encodes said antibody or the functional fragment thereof, an expression vector and a host cell for use in expressing said antibody or the functional fragment thereof, and a method for producing said antibody or the functional fragment thereof. An immunoconjugate and a pharmaceutical composition containing said antibody or the functional fragment thereof, and a method for using said antibody or the functional fragment thereof to enhance the function of a T cell so as to up-regulate a cell-mediated immune response, for use in treating diseases caused by T cell dysfunction.

Anti-PD-L1 antibody and application thereof

The present invention provides an antibody or a functional fragment thereof that specifically binds to Proprotein convertase subtilisin/kexin type 9 (PCSK9) with high affinity, also provides a nucleic acid molecule encoding the antibody of the invention or the functional fragment thereof, for expressing an expression vector and a host cell of the antibody or the functional fragment thereof, and also provides a method for producing the antibody or the functional fragment thereof. The present invention provides that the antibody or the functional fragment thereof is used for treating diseases such as dyslipidemia.

Anti-PCSK9 antibody and use thereof

This invention provides antibodies or functional fragments thereof that bind to PD-1 with high affinity. The invention provides nucleic acid molecules encoding the antibodies or the fragments thereof according to the present invention, expression vectors and host cells for expressing the antibodies or the functional fragments thereof according to the present invention, as well as methods for producing the antibodies or the functional fragments thereof according to the present invention. The present invention also provides immunoconjugates and pharmaceutical compositions comprising the antibodies or the functional fragments thereof according to the present invention. The present invention additionally provides methods for treating a plurality of diseases (comprising cancers, infectious diseases and inflammatory diseases) by using the antibodies or the functional fragments thereof disclosed herein.

Anti-PD-1 antibody and use thereof

The present invention belongs to the field of biopharmaceutics. Disclosed is an anti-BLyS antibody. The anti-BLyS antibody specifically targets BLyS, can combine with a B lymphocyte stimulating factor, and can inhibit the combination of the B lymphocyte stimulating factor with the receptor BR3-Fc thereof. Also provided are uses of the anti-BLyS antibody in the manufacture of a medicament for preventing and/or treating diseases caused by the excessive proliferation of B cells such as systemic lupus erythematorsus.

Anti-BLyS antibody

Growing community of inventors

Shanghai, China

Hui Feng